A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Anifrolumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors MedImmune
- 04 Oct 2017 Planned End Date changed from 20 Jul 2018 to 1 Aug 2018.
- 04 Oct 2017 Planned primary completion date changed from 20 Jul 2018 to 1 Aug 2018.
- 04 Oct 2017 Status changed from recruiting to active, no longer recruiting.